4RG0 image
Entry Detail
PDB ID:
4RG0
Title:
Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methyl-propanenitrile
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2014-09-29
Release Date:
2014-12-24
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.28
R-Value Work:
0.19
R-Value Observed:
0.20
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase BTK
Mutations:M489A, R492A, E624A, K625A
Chain IDs:A
Chain Length:283
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Finding the perfect spot for fluorine: Improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold.
Bioorg.Med.Chem.Lett. 25 367 371 (2015)
PMID: 25466710 DOI: 10.1016/j.bmcl.2014.11.030

Abstact

A rational fluorine scan based on co-crystal structures was explored to increase the potency of a series of selective BTK inhibitors. While fluorine substitution on a saturated bicyclic ring system yields no apparent benefit, the same operation on an unsaturated bicyclic ring can increase HWB activity by up to 40-fold. Comparison of co-crystal structures of parent molecules and fluorinated counterparts revealed the importance of placing fluorine at the optimal position to achieve favorable interactions with protein side chains.

Legend

Protein

Chemical

Disease

Primary Citation of related structures